Pharma-Bio Serv, Inc. engages in the provision of technical compliance consulting service and microbiological and chemical laboratory testing services to the pharmaceutical, chemical, medical device, and biotechnology industries. The firm operates through four segments: Puerto Rico technical compliance consulting, United States technical compliance consulting, Europe technical compliance consulting, and Puerto Rico microbiological and chemical laboratory testing division (Lab). The firm provides a range of compliance-related consulting services. The firm provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. The firm's technical consulting services include regulatory compliance, validation, technology transfer, engineering, project management and process support. The firm markets its services to pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies in Puerto Rico, the United States, Europe and Brazil.
How did PBSV's recent EPS compare to expectations?
The most recent EPS for Pharma-Bio Serv Inc is $0.0, not beating expectations of $0.02.
How did Pharma-Bio Serv Inc PBSV's revenue perform in the last quarter?
Pharma-Bio Serv Inc revenue for the last quarter is $0.0
What is the revenue estimate for Pharma-Bio Serv Inc?
According to 3 of Wall street analyst, the revenue estimate of Pharma-Bio Serv Inc range from $2.62M to $2.45M
What's the earning quality score for Pharma-Bio Serv Inc?
Pharma-Bio Serv Inc has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Pharma-Bio Serv Inc report earnings?
Pharma-Bio Serv Inc next earnings report is expected in 2026-06-15
What are Pharma-Bio Serv Inc's expected earnings?
Pharma-Bio Serv Inc expected earnings is $2.75M, according to wall-street analysts.
Did Pharma-Bio Serv Inc beat earnings expectations?
Pharma-Bio Serv Inc recent earnings of $2.29M does not beat expectations.